JAZZ - Jazz Pharmaceuticals plc


199.03
-3.530   -1.774%

Share volume: 990,797
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%

$202.56
-3.53
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
46%
Profitability 51%
Dept financing 12%
Liquidity 73%
Performance 41%
Company vs Stock growth
vs
Performance
5 Days
-2.16%
1 Month
9.17%
3 Months
16.39%
6 Months
43.68%
1 Year
92.52%
2 Year
82.88%
Key data
Stock price
$199.03
P/E Ratio 
0.00
DAY RANGE
$198.00 - $204.02
EPS 
-$5.84
52 WEEK RANGE
$97.50 - $207.48
52 WEEK CHANGE
$91.03
MARKET CAP 
10.330 B
YIELD 
N/A
SHARES OUTSTANDING 
61.560 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-30-2025
BETA 
0.75
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,044,565
AVERAGE 30 VOLUME 
$938,951
Company detail
CEO: Bruce C. Cozadd
Region: US
Website: jazzpharma.com
Employees: 3,200
IPO year: 2007
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Jazz Pharmaceuticals plc identifies, develops, commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi, Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the. treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for. adults with newly-diagn

Recent news